Jan. 4, 2013 The most comprehensive retrospective study ever conducted comparing how the major types of prostate cancer treatments stack up to each other in terms of saving lives and cost effectiveness is reported this week by a team of researchers at the University of California, San Francisco (UCSF).
Appearing in the British Journal of Urology International, the work analyzed 232 papers published in the last decade that report results from clinical studies following patients with low-, intermediate- and high-risk forms of prostate cancer who were treated with one or more of the standard treatments — radiation therapy, surgery, hormone therapies and brachytherapy.
The analysis shows that for people with low-risk prostate cancer, the various forms of treatment vary only slightly in terms of survival — the odds of which are quite good for men with this type of cancer, with a 5-year cancer-specific survival rate of nearly 100 percent. But the cost of radiation therapy is significantly more expensive than surgery for low-risk prostate cancer, they found.
For intermediate- and high-risk cancers, both survival and cost generally favored surgery over other forms of treatment — although combination external-beam radiation and brachytherapy together were comparable in terms of quality of life-adjusted survival for high-risk prostate cancer.
“Our findings support a greater role for surgery for high-risk disease than we have generally seen it used in most practice settings,” said urologist Matthew Cooperberg, MD, MPH who led the research. Cooperberg is an assistant professor of urology and epidemiology and biostatistics in the UCSF Helen Diller Family Comprehensive Cancer Center.
The UCSF Helen Diller Family Comprehensive Cancer Center is one of the country’s leading research and clinical care centers, and it is the only comprehensive cancer center in the San Francisco Bay Area.
Many Treatment Options, but Few Cost Analyses
Localized prostate cancer accounts for about 81 percent of the quarter-million cases of prostate cancers that occur in the United States every year, according to the National Cancer Institute. It is defined by tumors that have not metastasized and spread outside the prostate gland to other parts of the body.
There are multiple types of treatment for this form of the disease, including various types of surgery (open, laparoscopic or robot-assisted); radiation therapy (dose-escalated three-dimensional conformal radiation therapy, intensity-modulated radiation therapy and brachytherapy); hormone therapies; and combinations of each of these. Many men with low-risk prostate cancer do not need any of these treatments, and can be safely observed, at least initially.
Treatment plans for localized prostate cancer often vary dramatically from one treatment center to another. As Cooperberg put it, one person may have surgery, while someone across town with a very similar tumor may have radiation therapy, and a third may undergo active surveillance. All treatment regimens may do equally well.
“There is very little solid evidence that one [approach] is better than another,” said Cooperberg. The motivation for the new study, however, was that there are also few data examining the differences in terms of cost-effectiveness — the price to the health care system for every year of life gained, with adjustment for complications and side effects of treatments.
The new study was the most comprehensive cost analysis ever, and it compared the costs and outcomes associated with the various types of treatment for all forms of the disease, which ranged from $19,901 for robot-assisted prostatectomy to treat low-risk disease, to $50,276 for combined radiation therapy for high-risk disease.
The study did not consider two other approaches for dealing with prostate cancer: active surveillance, where patients with low-risk cancer are followed closely with blood tests and biopsies and avoid any initial treatment; and proton therapy, which is much more expensive and has already been shown in multiple studies not to be cost-effective, said Cooperberg.
The article, “Primary treatments for clinically localised prostate cancer: a comprehensive lifetime cost-utility analysis” is authored by Matthew R. Cooperberg, Naren R. Ramakrishna, Steven B. Duff, Kathleen E. Hughes, Sara Sadownik, Joseph A. Smith and Ashutosh K. Tewari. It was published online on Dec. 28, 2012 by the British Journal of Urology International.
In addition to UCSF, authors on the study are affiliated with Veritas Health Economics Consulting, Inc. in Carlsbad, CA; MD Anderson Cancer Center in Orlando, FL; Avalere Health LLC, in Washington, DC; Vanderbilt University in Nashville, TN; and Cornell University in New York.
In addition to UCSF and Kaiser Permanente, authors on this study are affiliated with the University of Washington in Seattle, the University of Michigan, Ann Arbor Veterans Affairs Health Care System in Michigan and the California Department of Public Health.
The work was supported by the National Cancer Institute, a component of the National Institutes of Health through grant #5RC1CA146596, and by the U.S. Agency for Healthcare Research and Quality through grant #1U01CA88160.
The cost effectiveness analysis in the paper was performed by Avalere Health LLC and Veritas Health Economics Consulting, Inc., which were both commissioned by Intuitive Surgical of Sunnyvale, CA. The authors report that the study sponsor had no role in the collection, analysis, or interpretation of the data; in writing or approving the manuscript; or in the decision to submit for publication.
UCSF is a leading university dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care.
Other social bookmarking and sharing tools:
Note: Materials may be edited for content and length. For further information, please contact the source cited above.
- Matthew R. Cooperberg, Naren R. Ramakrishna, Steven B. Duff, Kathleen E. Hughes, Sara Sadownik, Joseph A. Smith, Ashutosh K. Tewari. Primary treatments for clinically localised prostate cancer: a comprehensive lifetime cost-utility analysis. BJU International, 2013; DOI: 10.1111/j.1464-410X.2012.11597.x
Note: If no author is given, the source is cited instead.
Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.